Olink Target 48 Neurodegenerative Diseases
Research on neurodegenerative diseases using PEA technology, pioneering with the latest markers and absolute quantification.
Olink Target 48 Neurodegeneration is a high-performance proteomics panel specialized in neurodegenerative disease research. It can simultaneously measure 41 types of proteins, including the latest and important central nervous system biomarkers such as Aß40, Aß42, pTau217, NfL, and GFAP, which are gaining attention in Alzheimer's and Parkinson's disease research. This panel enables the acquisition of absolute quantification (ng/mL) data, which is difficult with other technologies, allowing for data comparison between studies and institutions, as well as high reproducibility in long-term longitudinal studies. With just 1µL of plasma or cerebrospinal fluid, high-sensitivity measurements can be achieved, maximizing the use of valuable clinical samples. Furthermore, by combining analyses with Olink's cytokine panel, it comprehensively captures neurodegeneration and neuroinflammation, significantly enhancing analytical power. The standardized workflow using the Signature Q100 system contributes broadly from basic research to clinical and drug discovery research.
